Encellin thin-film cell encapsulation (ENCRT / ENC-201)

What it is

Encellin is developing a thin, flexible, nanoporous thin-film pouch that holds insulin-producing cells and is implanted just under the skin — a strategy called Encapsulated Cell Replacement Therapy (ENCRT).¹ The membrane is engineered with pores small enough to keep the host's immune cells and antibodies out, but large enough to let glucose, oxygen, nutrients and insulin pass freely — so the cells can sense blood sugar and release insulin like a healthy islet would, in principle without lifelong immunosuppression.¹² The device is soft and roughly as thin as a human hair, and because it sits in the skin it can be retrieved or replaced.³

Where it came from

The technology was invented in Tejal Desai's lab at UC San Francisco and spun out by co-founder and CEO Crystal Nyitray.⁴ The foundational work showed that a thin-film device made from polycaprolactone (PCL) — a material already used in FDA-approved devices — could keep encapsulated insulin-secreting cells alive in mice for up to 90 days, triggering new blood-vessel growth around the device with little foreign-body reaction.⁴ A follow-up study used the nanoporous device to protect stem-cell-derived beta cells, showing engraftment and function out to 6 months in animals, immune isolation from the host, and — importantly for safety — prevention of stray stem cells escaping the device.⁵

The clinical evidence so far

The first-in-human study (NCT06408311, "ENC-201-CED") is a Phase 1 safety and tolerability trial in adults (18–70) with type 1 diabetes who receive donor (cadaveric) human islets sealed inside the device, run at the University Health Network in Toronto and McGill in Montreal; it began in 2024 and plans ~10 participants.⁶ Its main goal is device-related safety, with explants examined for islet survival and fibrosis — not insulin independence.⁶ In January 2026 Encellin reported interim results: in the first subjects, devices explanted at 4 months showed non-fibrotic engraftment with robust vascularization and viable human islets inside — the first human evidence that cells can persist in the device.⁷ No human insulin-independence or C-peptide efficacy data have been reported, and whether the approach truly avoids the need for immunosuppression in people is still being tested.⁶⁷ In animal models, islets in the Encellin device reportedly reversed diabetes with no fibrosis or immune response.¹

Durability, eligibility and safety

Durability is the make-or-break question for all encapsulation: past capsules failed because scar tissue (pericapsular fibrotic overgrowth) walls them off and starves the cells of oxygen.⁸ Encellin's thin-film, vascularization-promoting design is aimed squarely at that failure mode, and the early human explant data are encouraging — but long-term function is unproven.⁷⁸ Current eligibility mirrors standard islet-infusion candidates; broad reach ultimately depends on moving from scarce donor islets to a renewable stem-cell-derived cell source, which the platform is designed to accommodate but has not yet tested clinically.⁶⁵ The subcutaneous, retrievable placement is a meaningful safety advantage over grafts infused into the liver.³

What's coming

Encellin raised $9.9M led by Khosla Ventures (Dec 2023) to carry the device through this Phase 1 trial.⁹ Near-term, expect more explant and safety readouts from the donor-islet trial; longer-term, the company aims to pair the device with stem-cell-derived islets — the only way to make a cure scalable — and to extend the platform to other endocrine diseases.¹⁵ For now this is early-stage research: promising biology and a strong safety rationale, but no proof yet that it frees people from insulin.

References

References

1. Encellin / UCSF Innovation Ventures. Encellin Closes $9.9M Financing Led by Khosla Ventures to Advance Cell Encapsulation Platform for Endocrine Disorders. UCSF Innovation Ventures (2023). https://innovation.ucsf.edu/news/encellin-closes-99m-financing-led-khosla-ventures-advance-cell-encapsulation-platform-endocrine ↩ ↩² ↩³ ↩⁴

2. Encellin. Technology — Encapsulated Cell Replacement Therapy (ENCRT). Encellin (2026). https://www.encellin.com/technology ↩

3. On Track Diabetes. Diabetes Cure: Could a New Transplant Device Mean the End of Insulin Injections? On Track Diabetes (2026). https://www.ontrackdiabetes.com/type-1-diabetes/diabetes-cure-could-new-transplant-device-mean-end-insulin-injections ↩ ↩²

4. Nyitray CE, Chang R, Faleo G, Lance KD, Bernards DA, Tang Q, Desai TA. Polycaprolactone Thin-Film Micro- and Nanoporous Cell-Encapsulation Devices. ACS Nano (2015). https://pubmed.ncbi.nlm.nih.gov/25950860/ ↩ ↩²

5. Chang R, Faleo G, Russ HA, Parent AV, Elledge SK, Bernards DA, Allen JL, Villanueva K, Hebrok M, Tang Q, Desai TA. Nanoporous Immunoprotective Device for Stem-Cell-Derived β-Cell Replacement Therapy. ACS Nano (2017). https://pubmed.ncbi.nlm.nih.gov/28763191/ ↩ ↩² ↩³

6. Encellin. A Safety and Tolerability Study of ENC-201-CED in Participants With Type 1 Diabetes Receiving Islet Infusion (NCT06408311). ClinicalTrials.gov (2024). https://clinicaltrials.gov/study/NCT06408311 ↩ ↩² ↩³ ↩⁴

7. Encellin. Encellin Announces Interim Clinical Results Showing First-in-Human Non-Fibrotic Engraftment and Viable Encapsulated Human Islets in Subjects with Type 1 Diabetes. Encellin (2026). https://www.encellin.com/news/encellincloses99m-bjbbm-2cg4k ↩ ↩² ↩³

8. Vaithilingam V, Bal S, Tuch BE. Encapsulated Islet Transplantation: Where Do We Stand? Rev Diabet Stud (2017). https://pubmed.ncbi.nlm.nih.gov/28632821/ ↩ ↩²

9. Encellin. Encellin Closes $9.9M Financing Led by Khosla Ventures to Advance Cell Encapsulation Platform for Endocrine Disorders. Encellin (2023). https://www.encellin.com/news/encellincloses99m ↩